<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860336</url>
  </required_header>
  <id_info>
    <org_study_id>GO MOMs</org_study_id>
    <secondary_id>1U01DK123759-01</secondary_id>
    <secondary_id>5U01DK123759-02</secondary_id>
    <secondary_id>3U01DK123759-01S1</secondary_id>
    <secondary_id>1U01DK123783-01</secondary_id>
    <secondary_id>1U01DK123791-01</secondary_id>
    <secondary_id>1U01DK123795-01</secondary_id>
    <secondary_id>1U01DK123745-01</secondary_id>
    <secondary_id>1U01DK123799-01</secondary_id>
    <nct_id>NCT04860336</nct_id>
  </id_info>
  <brief_title>Glycemic Observation and Metabolic Outcomes in Mothers and Offspring</brief_title>
  <acronym>GO MOMs</acronym>
  <official_title>Glycemic Observation and Metabolic Outcomes in Mothers and Offspring / Glycemic Profile of Pregnancy Consortium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Women and Infants Hospital of Rhode Island</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of Glycemic Observation and Metabolic Outcomes in Mothers and Offspring&#xD;
      (GO MOMs) is to perform a comprehensive, longitudinal description of maternal glycemia over&#xD;
      the course of pregnancy and to evaluate how glucose levels throughout pregnancy relate to&#xD;
      traditional third trimester gestational diabetes mellitus (GDM) screening and perinatal&#xD;
      outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GO MOMs is an observational study designed to characterize the glycemic profile of pregnancy&#xD;
      using continuous glucose monitoring (CGM) technology in order to develop criteria using CGM&#xD;
      measurements and/or early pregnancy oral glucose tolerance testing (OGTT) at 10w0d-14w0d&#xD;
      gestation that are predictive, along with clinical factors, of adverse pregnancy outcomes in&#xD;
      mothers and their newborns. GO MOMs involves multiple institutions and an anticipated 2150&#xD;
      participants. Participants will attend 4 research study visits: Visit 1 (10w0d-14w0d&#xD;
      gestation), Visit 2 (16w0d-20w0d gestation), Visit 3 (24w0d-28w0d gestation), and Visit 4&#xD;
      (32w0d-36w0d gestation). Additional data will be collected at a Delivery Visit and via chart&#xD;
      abstraction. Mothers will have a Remote Follow-up call after delivery to collect additional&#xD;
      data. At Visits 1-4, a blinded CGM sensor will be placed. Participants will be instructed to&#xD;
      wear the sensor for 10 days after which time they will follow instructions to return it to&#xD;
      their study site. At Visit 1 (10w0d-14w0d gestation), participants will undergo a 75 g 2-hour&#xD;
      (hr) OGTT. At Visit 3 (24w0d-28w0d gestation), participants will undergo a 100 g 3 hr OGTT.&#xD;
      Visit 1 will include an extended maternal interview to collect social and demographic,&#xD;
      medical history, obstetrical history, surgical history, family medical history, current&#xD;
      health and pregnancy, and lifestyle (sleep, alcohol, tobacco use) data. Medical history,&#xD;
      alcohol and tobacco use data will be updated at each study visit. Sleep data will be updated&#xD;
      at Visit 3 (24w0d-28w0d gestation). Blood and urine samples will also be obtained at each&#xD;
      visit for additional laboratory testing and some will be stored for ancillary investigations.&#xD;
      At the Delivery Visit, newborn physical measurements including weight, length and skinfolds&#xD;
      will be performed. Birthweight at delivery will also be obtained through chart abstraction.&#xD;
      Primary statistical analyses will be performed to develop predictive criteria based on CGM&#xD;
      and/or OGTT measures at Visit 1 (10w0d-14w0d gestation) along with clinical factors for&#xD;
      primary maternal and newborn outcomes. Secondary analyses will further refine predictive&#xD;
      models and will evaluate associations of maternal glucose with secondary outcomes and&#xD;
      longitudinal modeling of maternal glycemia over the course of pregnancy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gestational diabetes (GDM)</measure>
    <time_frame>When participants are between 24 weeks 0 days pregnant to 28 weeks 0 days pregnant</time_frame>
    <description>Primary outcome in GO MOMs mothers: Number of mothers diagnosed with gestational diabetes mellitus (GDM) using a 100 g 3 hr OGTT at 24w0d-28w0d gestation according to Carpenter-Coustan criteria (at least two of the timed glucose measurements greater than or equal to the following thresholds: fasting &gt;= 95 mg/dL, 1 hr &gt;= 180 mg/dL, 2 hr &gt;= 155 mg/dL, 3 hr &gt;= 140 mg/dL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Large for gestational age (LGA)</measure>
    <time_frame>Delivery</time_frame>
    <description>Primary outcome in GO MOMs newborns: Number of newborns who are large for gestational age (LGA), defined as birthweight &gt;90th percentile for gestational age according to Aris et al. (2019). The first birthweight after delivery obtained from medical chart abstraction will be used for defining the primary LGA outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypertension</measure>
    <time_frame>Evaluated 30-90 days after delivery through chart abstraction for any events occurring during pregnancy</time_frame>
    <description>Secondary outcome in GO MOMs mothers: Number of mothers with hypertensive disorders of pregnancy including preeclampsia with and without severe features, gestational hypertension, eclampsia, and Hemolysis, Elevated Liver enzymes, and Low Platelet count (HELLP) syndrome, defined by the American College of Obstetricians and Gynecologists (ACOG) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cesarean delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Secondary outcome in GO MOMs mothers: Number of mothers with cesarean delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of skinfolds</measure>
    <time_frame>Within 72 hours after delivery</time_frame>
    <description>Secondary outcome in GO MOMs newborns: Newborn sum of flank, triceps, and subscapular skinfolds, evaluated as a continuous measure and dichotomized as &gt;90th percentile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small for gestational age (SGA)</measure>
    <time_frame>Delivery</time_frame>
    <description>Secondary outcome in GO MOMs newborns: Number of newborns who are small for gestational age (SGA), defined as birthweight &lt; 10th percentile for gestational age according to Aris et al. (2019)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preterm birth</measure>
    <time_frame>Delivery</time_frame>
    <description>Secondary outcome in GO MOMs newborns: Number of newborns with preterm birth, defined as delivery prior to estimated gestational age 37 weeks 0 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shoulder dystocia</measure>
    <time_frame>Delivery</time_frame>
    <description>Secondary outcome in GO MOMs newborns: Number of newborns with shoulder dystocia, identified through chart abstraction and defined clinically, requiring documentation that providers applied maneuvers to reduce the shoulder at delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal birth injury</measure>
    <time_frame>Delivery</time_frame>
    <description>Secondary outcome in GO MOMs newborns: Number of newborns with neonatal birth injury, identified through chart abstraction and defined as brachial plexus palsy or clavicular, humeral, or skull fracture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal hypoglycemia</measure>
    <time_frame>Within 30 days after delivery</time_frame>
    <description>Secondary outcome in GO MOMs newborns: Number of newborns with neonatal hypoglycemia, identified through chart abstraction and defined as treated neonatal hypoglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal respiratory morbidity</measure>
    <time_frame>Within 30 days after delivery</time_frame>
    <description>Secondary outcome in GO MOMs newborns: Number of newborns with neonatal respiratory morbidity, identified through chart abstraction and defined as need for respiratory support within 72 hrs after birth and consisting of one or more of the following: the use of continuous positive airway pressure (CPAP) or high-flow nasal cannula for at least 2 consecutive hrs, supplemental oxygen with a fraction of inspired oxygen of at least 0.30 for at least 4 continuous hrs, extracorporeal membrane oxygenation (ECMO), or mechanical ventilation. A high flow of air or blended air and oxygen is defined as more than 1 liter per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal hyperbilirubinemia</measure>
    <time_frame>Within 30 days after delivery</time_frame>
    <description>Secondary outcome in GO MOMs newborns: Number of newborns with neonatal hyperbilirubinemia, identified through chart abstraction and defined as treatment of hyperbilirubinemia in the first week of life with phototherapy or exchange transfusion or a diagnosis of kernicterus.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Neonatal intensive care unit (NICU) admissions</measure>
    <time_frame>WIthin 30 days after delivery</time_frame>
    <description>Exploratory outcome in GO MOMs newborns: Number of newborns with neonatal intensive care unit (NICU) admissions</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospital admission</measure>
    <time_frame>Within 30 days after delivery</time_frame>
    <description>Exploratory outcome in GO MOMs newborns: Length of admission/length of stay (for NICU or entire delivery hospitalization) for newborns</description>
  </other_outcome>
  <other_outcome>
    <measure>Spontaneous abortion</measure>
    <time_frame>Prior to 20 weeks' gestation</time_frame>
    <description>Exploratory outcome in GO MOMs mothers: Spontaneous abortion (&lt; 20 weeks of gestation)</description>
  </other_outcome>
  <other_outcome>
    <measure>Stillbirth</measure>
    <time_frame>Delivery</time_frame>
    <description>Exploratory outcome in GO MOMs newborns: Number of mothers with stillbirth (intrauterine fetal demise at 20 weeks of gestation or later)</description>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal death</measure>
    <time_frame>Within 30 days after delivery</time_frame>
    <description>Exploratory outcome in GO MOMs newborns: Number of newborns with neonatal death</description>
  </other_outcome>
  <other_outcome>
    <measure>Major congenital malformation</measure>
    <time_frame>Within 30 days after delivery</time_frame>
    <description>Exploratory outcome in GO MOMs newborns: Number of newborns with major congenital malformation</description>
  </other_outcome>
  <other_outcome>
    <measure>Antepartum admissions or maternal readmissions</measure>
    <time_frame>Within 30 days after delivery</time_frame>
    <description>Exploratory outcome in GO MOMs mothers: Number of mothers with antepartum admissions or maternal readmissions</description>
  </other_outcome>
  <other_outcome>
    <measure>Apgar score &lt;7 at 5 minutes</measure>
    <time_frame>Delivery</time_frame>
    <description>Exploratory outcome in GO MOMs newborns: Number of newborns with Apgar score &lt;7 at 5 minutes</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2150</enrollment>
  <condition>Gestational Diabetes</condition>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>Pregnant women less than or equal to 14w0d gestation</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>Observational</description>
    <arm_group_label>Pregnant women less than or equal to 14w0d gestation</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Participants are given the option to have blood collected for future DNA analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant adults who enroll prior to 10w0d-14w0d gestation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Maternal age &gt;=18 at consent&#xD;
&#xD;
          -  Singleton gestation&#xD;
&#xD;
          -  10w0d-14w0d gestation at the time of the Visit 1 OGTT and CGM placement according to&#xD;
             study dating criteria&#xD;
&#xD;
          -  Conceived using own oocyte&#xD;
&#xD;
          -  Willing and able to wear CGM as directed and adhere to CGM instructions&#xD;
&#xD;
          -  Planning to deliver at GO MOMs-affiliated hospital (see list of accrual sites in the&#xD;
             protocol section &quot;Key Roles and Contact Information&quot;).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing diabetes at enrollment&#xD;
&#xD;
          -  Currently self-monitoring blood glucose&#xD;
&#xD;
          -  Current use of medication with glycemic effects&#xD;
&#xD;
          -  Fetal malformation evident at or before enrollment that is likely lethal. This&#xD;
             includes, but is not limited to, malformations such as anencephaly, hydrops, diffuse&#xD;
             subcutaneous edema or cystic hygroma, ectopic cordis, and encephalocele&#xD;
&#xD;
          -  Known fetal aneuploidy based on chorionic villus sampling&#xD;
&#xD;
          -  Participation in other research study that may modify glycemic profile or study&#xD;
             outcomes&#xD;
&#xD;
          -  History of bariatric surgery&#xD;
&#xD;
          -  Extensive skin changes or diseases making CGM sensor use problematic&#xD;
&#xD;
          -  Significant allergy to adhesive&#xD;
&#xD;
          -  Previous participation in GO MOMs&#xD;
&#xD;
          -  Current bulimia or anorexia nervosa&#xD;
&#xD;
          -  Overnight shift work that alters the sleep/wake periods&#xD;
&#xD;
          -  Hemoglobin A1c &gt;= 6.5%, fasting glucose &gt;= 126 mg/dL or 2 hr glucose &gt;= 200 mg/dL&#xD;
             noted during OGTT at 10w0d-14w0d gestation&#xD;
&#xD;
          -  Current psychiatric illness/social situation that would limit compliance with study&#xD;
             requirements, as determined by the site investigator&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise Scholtens, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Beth Tull, MS</last_name>
    <phone>1 312 503 4746</phone>
    <email>gomoms@northwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Bustamante, MPH</last_name>
    <phone>1 312 503 5512</phone>
    <email>p-bustamante@northwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uma Reddy, MD, MPH</last_name>
      <phone>203-785-5855</phone>
      <email>uma.reddy@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Sherr, MD, PhD</last_name>
      <phone>(203)-785-5831</phone>
      <email>jennifer.sherr@yale.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teresa Hillier, MD, MS</last_name>
      <phone>503-335-2478</phone>
      <email>teresa.hillier@kpchr.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William Grobman, MD, MBA</last_name>
      <phone>312-472-4685</phone>
      <email>w-grobman@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Denise Scholtens, PhD</last_name>
      <phone>1 312 503 7261</phone>
      <email>dscholtens@northwestern.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandra Spadola, MD</last_name>
      <phone>617-636-2382</phone>
      <email>aspadola@tuftsmedicalcenter.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille Powe, MD</last_name>
      <phone>617-643-4684</phone>
      <email>Camille.Powe@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noelia Zork, MD</last_name>
      <phone>347-514-0034</phone>
      <email>nmz2110@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Northwest</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erin LeBlanc</last_name>
      <phone>503-528-3996</phone>
      <email>erin.s.leblanc@kpchr.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Magee Womens Research Institute &amp; Foundation</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesca Facco, MD</last_name>
      <phone>412-641-5406</phone>
      <email>faccof@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erika Werner, MD, MS</last_name>
      <phone>401-274-1122</phone>
      <phone_ext>47443</phone_ext>
      <email>ewerner@wihri.org</email>
    </contact>
    <contact_backup>
      <last_name>Dwight Rouse, MD, MSPH</last_name>
      <email>DRouse@Wihri.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.gomomsstudy.org</url>
    <description>Information about the study</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Denise Scholtens</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>gestational diabetes</keyword>
  <keyword>continuous glucose monitor</keyword>
  <keyword>oral glucose tolerance test</keyword>
  <keyword>gestational diabetes mellitus</keyword>
  <keyword>GDM</keyword>
  <keyword>OGTT</keyword>
  <keyword>CGM</keyword>
  <keyword>glucose tolerance test</keyword>
  <keyword>glycemic regulation</keyword>
  <keyword>pregnancy</keyword>
  <keyword>large for gestational age</keyword>
  <keyword>observational</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Participants have the option to agree to share dataset with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Repository.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

